QUANTITATIVE-ANALYSIS OF HEPATITIS-C VIRUS-RNA - RELATIONSHIP BETWEEN THE REPLICATIVE LEVEL AND THE VARIOUS STAGES OF THE CARRIER STATES OR THE RESPONSE TO INTERFERON THERAPY

被引：10

作者：

HAGIWARA, H

HAYASHI, N

FUSAMOTO, H

KAMADA, T

机构：

[1] The First Department of Medicine, Osaka University Medical School, Suita, 565

来源：

GASTROENTEROLOGIA JAPONICA | 1993年 / 28卷

关键词：

D O I：

10.1007/BF02989205

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The authors quantified hepatitis C virus (HCV) RNA in serum by the competitive RT-PCR assay to correlate the replicative level of HCV with [1] various stages of the carrier states or [2] a sustained response to inteferon therapy. The competitive RT-PCR assay employed is based on coamplification of the target RNA with known amounts of synthetic mutated RNA having a novel restriction endonuclease (EcoRI) site. The titer of circulating HCV RNA defined as log10 (copy numbers/ml serum) were lower in asymptomatic blood donors (5.4±2.0) and in patients with chronic persistent hepatitis (7.3± 1.1) compared with those having chronic active hepatitis (7.9±0.8), liver cirrhosis (7.8±0.7) and hepatocellular carcinoma (7.9±0.7). The initial titer of circulating HCV RNA of long-term responders before interferon therapy (7.1±1.2) was significantly lower than that of short-term responders (8.+-0.5) and non-responders (8.1±0.4). Multivariate multiple logistic regression showed that the titer of HCV RNA before therapy was the strongest independent predictor of a sustained response to interferon therapy. These results showed that the replicative level of hepatitis C virus is higher in advanced liver disease and that the replicative state of HCV is the most important factor influencing sustained response to interferon treatment. © 1993 The Japanese Society of Gastroenterology.

引用

页码：48 / 51

页数：4

共 10 条

[1]

Kuo G., Choo Q.L., Alter H.J., Et al., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis, Science, 244, pp. 362-364, (1989)

[2]

Alter H.J., Purcell R.H., Shih J.W., Et al., Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis, N Engl J Med, 321, pp. 1494-1500, (1989)

[3]

Hopf U., Moller B., Kuther D., Et al., Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV), J Hepatol, 10, pp. 69-76, (1990)

[4]

Hagiwara H., Hayashi N., Mita E., Et al., Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease, Gastroenterology, 102, pp. 692-694, (1992)

[5]

Yuki N., Hayashi N., Kasahara A., Et al., Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinoma, Dig Dis Sci, 37, pp. 65-72, (1992)

[6]

Davis G.L., Balart L.A., Schiff E.R., Et al., Treatment of chronic hepatitis C with recombinant interferon alfa A multicenter randomized, controlled trial, N Engl J Med, 321, pp. 1501-1506, (1989)

[7]

Di Bisceglie A.M., Martin P., Kassianides C., Et al., Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial, N Engl J Med, 321, pp. 1506-1510, (1989)

[8]

Hagiwara H., Hayashi N., Mita E., Et al., Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α, Hepatology, 15, pp. 37-41, (1992)

[9]

Hagiwara H., Hayashi N., Mita E., Et al., Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy, Gastroenterology, 104, pp. 877-883, (1993)

[10]

Takamizawa A., Mori C., Fuke I., Et al., Structure and organization of the hepatitis C virus genome isolated from human carriers, J Virol, 65, pp. 1105-1113, (1991)

← 1 →